By Anna Rose Welch, editor, Biosimilar Development
Multibiosimilar competition in the U.S. oncology space, as well as the FDA’s regulatory progress toward a more competitive insulin market, are popular topics the Biosimilar Development editorial board is watching. But these are hardly the only big 2020 events to note in this progressing industry.
The industry has shown surprising resilience and consistency, emerging relatively unscathed from the recession at the beginning of the past decade. Capacity and expansion were relatively unaffected and continue to draw investors seeking healthy returns and a recession-resistant risk profile.
By Enrique Carredano,GE Healthcare Life Sciences
There is a limit to how many stainless-steel tanks you can squeeze into a biomanufacturing facility. Is automated buffer preparation a solution to the dilemma of balancing increased production capacity against limited footprint expansion alternatives?